China Pharma Holdings, Inc.
CPHI
$1.43
$0.0151.06%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -29.64% | -33.10% | -35.41% | -28.76% | -21.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.64% | -33.10% | -35.41% | -28.76% | -21.36% |
| Cost of Revenue | -32.63% | -14.55% | -10.67% | -6.21% | -1.79% |
| Gross Profit | 44.16% | -144.52% | -606.12% | -1,095.35% | -2,431.77% |
| SG&A Expenses | 20.52% | 1.97% | 3.97% | -8.73% | -11.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.07% | -9.95% | -6.61% | -3.77% | -1.90% |
| Operating Income | 15.80% | -35.50% | -66.76% | -67.28% | -55.10% |
| Income Before Tax | 16.97% | -28.31% | -53.84% | -52.50% | -40.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.97% | -28.31% | -53.84% | -52.50% | -40.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.97% | -28.31% | -53.84% | -52.50% | -40.97% |
| EBIT | 15.80% | -35.50% | -66.76% | -67.28% | -55.10% |
| EBITDA | -28.99% | -379.13% | -109,594.44% | -15,182.14% | -4,002.12% |
| EPS Basic | 74.70% | 73.94% | 74.88% | 79.46% | 74.18% |
| Normalized Basic EPS | 74.70% | 73.94% | 74.88% | 79.46% | 74.18% |
| EPS Diluted | 74.70% | 73.94% | 74.88% | 79.46% | 74.18% |
| Normalized Diluted EPS | 74.70% | 73.94% | 74.88% | 79.46% | 74.18% |
| Average Basic Shares Outstanding | 168.22% | 257.29% | 427.87% | 646.86% | 603.95% |
| Average Diluted Shares Outstanding | 168.22% | 257.29% | 427.87% | 646.86% | 603.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |